EP2229180A1 - Composition comprenant de la superoxyde dismutase et du beta-1,3 glucane carboxy méthyle - Google Patents

Composition comprenant de la superoxyde dismutase et du beta-1,3 glucane carboxy méthyle

Info

Publication number
EP2229180A1
EP2229180A1 EP07866845A EP07866845A EP2229180A1 EP 2229180 A1 EP2229180 A1 EP 2229180A1 EP 07866845 A EP07866845 A EP 07866845A EP 07866845 A EP07866845 A EP 07866845A EP 2229180 A1 EP2229180 A1 EP 2229180A1
Authority
EP
European Patent Office
Prior art keywords
composition
glucan
superoxide dismutase
methyl beta
sodium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07866845A
Other languages
German (de)
English (en)
Inventor
Luigi Mercuri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DMG Italia SRL
Original Assignee
DMG Italia SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DMG Italia SRL filed Critical DMG Italia SRL
Publication of EP2229180A1 publication Critical patent/EP2229180A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/446—Superoxide dismutase (1.15)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y115/00—Oxidoreductases acting on superoxide as acceptor (1.15)
    • C12Y115/01—Oxidoreductases acting on superoxide as acceptor (1.15) with NAD or NADP as acceptor (1.15.1)
    • C12Y115/01001—Superoxide dismutase (1.15.1.1)

Definitions

  • composition comprising superoxide dismutase and carboxy methyl beta 1,3- glucan Description of the invention
  • the present invention refers to the pharmaceutical field and in particular to a composition comprising superoxide dismutase and carboxy methyl beta 1-3 glucan in the form of liposomes or phosphoglucan to be used in the ophthalmic field for preventing the corneal epithelium degeneration caused by aging and oxidative stress.
  • CGM carboxy methyl beta 1-3 glucan
  • CGM is preferably in aqueous solution and more preferably in a concentration from 0,2 % to 2%.
  • the pharmaceutical preparation for ophthalmic use comprises CGM 0,5%, N-hydroxymethyl glicinate 0,001%, sodium edetate 0,1% and isotonic solution pH 7,2.
  • the International patent application N. PCT/IT2006/000543 discloses a pharmaceutical preparation for ophthalmic use or for oral administration comprising sodium carboxymethyl-beta-1,3- glucan CGM inside liposomes or bound to the liposome membrane, able to improve the lubrication of the eye and to protect the eye from irritation.
  • the complex between sodium CGM and liposomes is preferably in a concentration from 0,1% to 50%, more preferably from 0,1 % to 5%.
  • the same application discloses a cosmetic composition, comprising the same sodium CGM/liposomes complex, with a protective and regenerative effect on the skin.
  • CGM/liposomes complexs with a diameter lower than 100 ⁇ m, preferably lower than 50 ⁇ m, is disclosed.
  • said combination has a lubricating, moisturizing, antioxidative and photoprotective effect and it is particularly suitable for the protection and the treatment of eye degeneration caused by oxidative stresses, such as the exposure to light radiations or laser bean during refractive surgery, it is also suitable for the prevention and the treatment of cataract.
  • composition comprising superoxide dismutase and carboxy methyl 1,3-glucan CGM.
  • a further object of the present invention is a composition comprising superoxide dismutase and a sodium carboxy methyl 1,3-glucan/liposome complex as described in PCT/IT2006/000543, herein included by reference.
  • superoxide dismutase is in a concentration from 0,001% to 2% and CGM is in a concentration from 0,01 % to 5 %.
  • the composition, object of the present invention is used for the preparation of a medicament for the treatment and the prevention of corneal epithelium degeneration due to aging and oxidative stress caused by photoexposure.
  • Said medicament is preferably formulated as a collyrium.
  • the person with ordinary skills in the pharmaceutical field can appropriately add pharmaceutically acceptable adjuvants, carriers and excipients to be used in the preparation of collyrium.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Cette invention concerne une composition comprenant de la superoxyde dismutase et du bêta-1,3 glucane carboxy méthyle pour prévenir la dégénérescence de l'épithélium cornéen induit par l'âge et le stress oxydatif.
EP07866845A 2007-12-27 2007-12-27 Composition comprenant de la superoxyde dismutase et du beta-1,3 glucane carboxy méthyle Withdrawn EP2229180A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IT2007/000914 WO2009084044A1 (fr) 2007-12-27 2007-12-27 Composition comprenant de la superoxyde dismutase et du beta-1,3 glucane carboxy méthyle

Publications (1)

Publication Number Publication Date
EP2229180A1 true EP2229180A1 (fr) 2010-09-22

Family

ID=39731080

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07866845A Withdrawn EP2229180A1 (fr) 2007-12-27 2007-12-27 Composition comprenant de la superoxyde dismutase et du beta-1,3 glucane carboxy méthyle

Country Status (3)

Country Link
EP (1) EP2229180A1 (fr)
IL (1) IL206273A0 (fr)
WO (1) WO2009084044A1 (fr)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1277707B1 (it) * 1995-12-22 1997-11-11 Chemedica Sa Formulazione oftalmica a base di ialuronato di sodio per uso nella chirurgia oculare
AU1944599A (en) * 1997-12-24 1999-07-19 Shaklee Corporation Composition with high efficiency skin protection from damaging effects of ultraviolet light
US7011845B2 (en) * 2000-05-09 2006-03-14 Mcp Hahnemann University β-glucans encapsulated in liposomes
DE60216612T2 (de) * 2002-06-10 2007-09-20 D.M.G. Italia S.R.L. Carboxy Methyl Beta-1,3 Glucan enthaltende ophthalmische Lösung

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2009084044A1 *

Also Published As

Publication number Publication date
IL206273A0 (en) 2010-12-30
WO2009084044A1 (fr) 2009-07-09

Similar Documents

Publication Publication Date Title
JP2005104862A (ja) 加齢黄斑変性治療剤
WO2020021481A1 (fr) Compositions et méthodes de traitement de l'œil
JP5167499B2 (ja) 光角膜切除における角膜組織の保護のためのピレノキシンの使用
JP3362501B2 (ja) 角膜障害治療剤
US11878041B2 (en) Compositions and methods for treating the eye
JP2005516017A (ja) 向上した薬物動態特性を示す医薬コンジュゲート
AU2019311849B2 (en) Compositions and methods for treating the eye
AU2022263530A1 (en) Compositions and methods for treating the eye
EP2229180A1 (fr) Composition comprenant de la superoxyde dismutase et du beta-1,3 glucane carboxy méthyle
JP2011144111A (ja) 軸性近視の予防または治療剤
RU2795913C2 (ru) Композиции и способы лечения глаз
RU2792627C2 (ru) Композиции и способы лечения глаз
EP3824877A1 (fr) Compositions et procédés pour le traitement de l' il
US11969451B2 (en) Compositions and methods for treating the eye
RU2793736C2 (ru) Композиции и способы лечения глаз
US8916543B1 (en) Inhibitors of alpha-toxin
WO2022079664A1 (fr) Chlorure de benzalkonium pour une utilisation dans le traitement de la conjonctivite et/ou de la covid-19
RU2171659C2 (ru) Способ медикаментозного лечения кератоконуса
JP2005200411A (ja) 涙液層安定化剤
WO2005058932A1 (fr) Stabilisateur du film lacrymal

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20100705

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

RTI1 Title (correction)

Free format text: COMPOSITION COMPRISING SUPEROXIDE DISMUTASE AND CARBOXY METHYL BETA-1,3 GLUCAN

17Q First examination report despatched

Effective date: 20130624

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20140329